FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308272153> ?p ?o ?g. }

• W4308272153 endingPage "528" @default.
• W4308272153 startingPage "515" @default.
• W4308272153 abstract "The Global Initiative for Chronic Obstructive Lung Disease (GOLD) considers blood eosinophil counts < 100 cells/μL (BEC≤100) in people with COPD to predict poor inhaled corticosteroid (ICS) responsiveness. However, the BEC≤100 phenotype is inadequately characterized, especially in advanced COPD.Are there differences between GOLD group D patients with high BEC and those with low BEC regarding baseline characteristics and longitudinal outcomes?We used multivariable mixed models and logistic regression to contrast clinical characteristics and outcomes of BEC≤100 vs BEC > 100 (BEC100+) in all subjects with COPD (n = 1,414) and GOLD group D subjects (n = 185) not receiving ICS.We identified n = 485 with BEC≤100 (n = 61 GOLD group D) and n = 929 people with BEC100+ (n = 124 GOLD group D). BEC≤100 status was stable at 6 weeks and approximately 52 weeks (intraclass correlations of 0.78 and 0.71, respectively). Compared with BEC100+, BEC≤100 comprised more women, with greater current smoking, and less frequent childhood asthma. Among all analyzed participants, the two BEC-defined subsets showed similar rates of lung function decline (mean slope, BEC≤100 vs BEC100+, -50 vs -39 mL/y; P = .140), exacerbations (0.40 vs 0.36/y; P = .098), subsequent ICS initiation (2.5% vs 4.4%; P = .071), and mortality (7.8% vs 8.4%; P = .715). However, in GOLD group D, people with BEC≤100 showed higher exacerbation rates within 365 days of enrollment (0.62 vs 0.33/y; P = .002) and total follow-up (1.16 vs 0.83/y; P = .014). They also had greater lung function decline (mean slope of -68 mL/y vs -23 mL/y; P = .036) and had greater emphysema at baseline (voxels < 950 Hounsfield units at total lung capacity of 7.46% vs 4.61%; P = .029).In non-ICS-treated GOLD group D COPD, people with BEC≤100 had more baseline emphysema, prospective exacerbations, and lung function decline. Our analysis has identified a particularly vulnerable subpopulation of people with COPD, suggesting the need for studies focused specifically on their therapeutic treatment.ClinicalTrials.gov; No.: NCT01969344; URL: www.gov." @default.
• W4308272153 created "2022-11-10" @default.
• W4308272153 creator A5016761421 @default.
• W4308272153 creator A5017665414 @default.
• W4308272153 creator A5018253356 @default.
• W4308272153 creator A5026096786 @default.
• W4308272153 creator A5031555717 @default.
• W4308272153 creator A5032438300 @default.
• W4308272153 creator A5038975290 @default.
• W4308272153 creator A5044888615 @default.
• W4308272153 creator A5045141623 @default.
• W4308272153 creator A5048656238 @default.
• W4308272153 creator A5052110481 @default.
• W4308272153 creator A5052471232 @default.
• W4308272153 creator A5054579636 @default.
• W4308272153 creator A5055201103 @default.
• W4308272153 creator A5060911765 @default.
• W4308272153 creator A5062711392 @default.
• W4308272153 creator A5067983207 @default.
• W4308272153 creator A5068244386 @default.
• W4308272153 creator A5080219607 @default.
• W4308272153 creator A5082568705 @default.
• W4308272153 creator A5086501700 @default.
• W4308272153 creator A5087218579 @default.
• W4308272153 creator A5089417042 @default.
• W4308272153 date "2023-03-01" @default.
• W4308272153 modified "2023-10-02" @default.
• W4308272153 title "Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort" @default.
• W4308272153 cites W1859222707 @default.
• W4308272153 cites W1987881697 @default.
• W4308272153 cites W1991844584 @default.
• W4308272153 cites W2009051503 @default.
• W4308272153 cites W2061435251 @default.
• W4308272153 cites W2087387762 @default.
• W4308272153 cites W2113430717 @default.
• W4308272153 cites W2116954144 @default.
• W4308272153 cites W2120397327 @default.
• W4308272153 cites W2125078269 @default.
• W4308272153 cites W2126384628 @default.
• W4308272153 cites W2142724633 @default.
• W4308272153 cites W2155765761 @default.
• W4308272153 cites W2327037637 @default.
• W4308272153 cites W2482855087 @default.
• W4308272153 cites W2583265473 @default.
• W4308272153 cites W2594716548 @default.
• W4308272153 cites W2760264579 @default.
• W4308272153 cites W2766837472 @default.
• W4308272153 cites W2769297698 @default.
• W4308272153 cites W2770113020 @default.
• W4308272153 cites W2773432295 @default.
• W4308272153 cites W2783705291 @default.
• W4308272153 cites W2788945727 @default.
• W4308272153 cites W2789413626 @default.
• W4308272153 cites W2791355082 @default.
• W4308272153 cites W2796428321 @default.
• W4308272153 cites W2800157982 @default.
• W4308272153 cites W2802221596 @default.
• W4308272153 cites W2883310045 @default.
• W4308272153 cites W2889568903 @default.
• W4308272153 cites W2898885300 @default.
• W4308272153 cites W2937862696 @default.
• W4308272153 cites W2946147704 @default.
• W4308272153 cites W2955803684 @default.
• W4308272153 cites W2998158733 @default.
• W4308272153 cites W2998646242 @default.
• W4308272153 cites W2999350597 @default.
• W4308272153 cites W3037411127 @default.
• W4308272153 cites W3110944743 @default.
• W4308272153 doi "https://doi.org/10.1016/j.chest.2022.10.029" @default.
• W4308272153 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36343688" @default.
• W4308272153 hasPublicationYear "2023" @default.
• W4308272153 type Work @default.
• W4308272153 citedByCount "2" @default.
• W4308272153 countsByYear W43082721532023 @default.
• W4308272153 crossrefType "journal-article" @default.
• W4308272153 hasAuthorship W4308272153A5016761421 @default.
• W4308272153 hasAuthorship W4308272153A5017665414 @default.
• W4308272153 hasAuthorship W4308272153A5018253356 @default.
• W4308272153 hasAuthorship W4308272153A5026096786 @default.
• W4308272153 hasAuthorship W4308272153A5031555717 @default.
• W4308272153 hasAuthorship W4308272153A5032438300 @default.
• W4308272153 hasAuthorship W4308272153A5038975290 @default.
• W4308272153 hasAuthorship W4308272153A5044888615 @default.
• W4308272153 hasAuthorship W4308272153A5045141623 @default.
• W4308272153 hasAuthorship W4308272153A5048656238 @default.
• W4308272153 hasAuthorship W4308272153A5052110481 @default.
• W4308272153 hasAuthorship W4308272153A5052471232 @default.
• W4308272153 hasAuthorship W4308272153A5054579636 @default.
• W4308272153 hasAuthorship W4308272153A5055201103 @default.
• W4308272153 hasAuthorship W4308272153A5060911765 @default.
• W4308272153 hasAuthorship W4308272153A5062711392 @default.
• W4308272153 hasAuthorship W4308272153A5067983207 @default.
• W4308272153 hasAuthorship W4308272153A5068244386 @default.
• W4308272153 hasAuthorship W4308272153A5080219607 @default.
• W4308272153 hasAuthorship W4308272153A5082568705 @default.
• W4308272153 hasAuthorship W4308272153A5086501700 @default.
• W4308272153 hasAuthorship W4308272153A5087218579 @default.
• W4308272153 hasAuthorship W4308272153A5089417042 @default.

• next